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The drug class we originally termed ‘Reversed Chloro-
quines’ has been assessed, via SAR, to select a candidate
for preclinical evaluation. Such molecules were originally
designed to function like the late-20th century Gold-
standard, chloroquine, but with an appendage that
intentionally inhibits resistance. Thus, PL69/DM1157
was subjected to screening, beginning with potency
against many laboratory-adapted strains of chloroquine-
resistant P. falciparum and in vivo efficacy in mice.
PL69/DM1157, having structural features in common
with chloroquine, might have cardiac effects, so we eval-
uated for hERG interaction, but more rigorously in a
guinea pig electrocardiogram model. The results indi-
cated the cardiac safety to be similar to chloroquine.
Academic collaborators have subjected PL69/DM1157
to clinical isolates of highly resistant P. falciparum, as
well as to P. vivax strains. A chloroquine-resistant strain
of P. falciparum was also subjected to PL69/DM1157
pressure for over two years in an unsuccessful attempt to
increase IC50.
The project has now progressed through off-target eva-
luations, in vitro toxicity assessments, and rat preclinical
toxicity tests. The molecule has been synthesized under
GLP certification, without chlorinated solvents or any
chromatographic steps to >99% purity, at sufficient scale
to permit final toxicity evaluation in a second species, as
well as in a Phase-I clinical trial, using the same batch.
This work also demonstrates how collaboration between
a university and a start-up company can be an alternative
pathway to bring a neglected-disease drug through the
necessary drug development steps. The experience gained
through this and other malaria work has enabled the com-
pany to begin collaborative work on drug-resistant bacter-
ial diseases as well.
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